GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OmniAb Inc (NAS:OABI) » Definitions » Price-to-Free-Cash-Flow

OmniAb (OmniAb) Price-to-Free-Cash-Flow : 507.78 (As of May. 09, 2024)


View and export this data going back to 2022. Start your Free Trial

What is OmniAb Price-to-Free-Cash-Flow?

As of today (2024-05-09), OmniAb's share price is $4.57. OmniAb's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01. Hence, OmniAb's Price-to-Free-Cash-Flow Ratio for today is 507.78.

The historical rank and industry rank for OmniAb's Price-to-Free-Cash-Flow or its related term are showing as below:

OABI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 120   Med: 518.89   Max: 716.67
Current: 504.44

During the past 5 years, OmniAb's highest Price-to-Free-Cash-Flow Ratio was 716.67. The lowest was 120.00. And the median was 518.89.

OABI's Price-to-Free-Cash-Flow is ranked worse than
95.85% of 217 companies
in the Biotechnology industry
Industry Median: 31.15 vs OABI: 504.44

OmniAb's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.09. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.01.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -24.10% per year.

During the past 5 years, OmniAb's highest 3-Year average Free Cash Flow per Share Growth Rate was -24.10% per year. The lowest was -72.90% per year. And the median was -48.50% per year.


OmniAb Price-to-Free-Cash-Flow Historical Data

The historical data trend for OmniAb's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OmniAb Price-to-Free-Cash-Flow Chart

OmniAb Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - - 881.43

OmniAb Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 126.90 - - 881.43

Competitive Comparison of OmniAb's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, OmniAb's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OmniAb's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OmniAb's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where OmniAb's Price-to-Free-Cash-Flow falls into.



OmniAb Price-to-Free-Cash-Flow Calculation

OmniAb's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=4.57/0.009
=507.78

OmniAb's Share Price of today is $4.57.
OmniAb's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

OmniAb  (NAS:OABI) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


OmniAb Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of OmniAb's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


OmniAb (OmniAb) Business Description

Traded in Other Exchanges
N/A
Address
5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608
OmniAb Inc offers therapeutic antibody discovery technologies. Its focus is to enable the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully-human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Executives
Matthew W Foehr director, officer: President & CEO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Steven Love director C/O OMNIAB, INC., 5980 HORTON STREET, SUITE 600, EMERYVILLE CA 94608
Carolyn R Bertozzi director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
John L Higgins director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Avista Capital Managing Member V, Llc director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V Gp, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners (offshore) V, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Thompson Dean director, 10 percent owner 65 EAST 55TH STREET, 18TH FLOOR, C/O AVISTA CAPITAL PARTNERS, NEW YORK NY 10022
Avista Acquisition Lp Ii director, 10 percent owner C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Acquisition Gp Llc Ii director, 10 percent owner C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
David F Burgstahler director, 10 percent owner C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Kurt A Gustafson officer: EVP, Finance and CFO 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Sarah Boyce director C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010